Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease

Related Articles
Anumana Welcomes Dr. Simos Kedikoglou as New COO
Investor Hangout: Anumana, a prominent player in AI-driven health technology, has recently appointed Dr. Simos Kedikoglou as its new President and Chief Operating Officer (COO). This exciting change will see…January 10, 2025
Anumana Appoints Maulik Nanavaty as CEO
Anumana Appoints Maulik Nanavaty as CEOCAMBRIDGE, Mass. – October 19, 2023 – Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, today announced that Maulik Nanavaty…October 19, 2023
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
Novartis Pharmaceuticals Corporation to collaborate on development of new medical device software for earlier detection and intervention in cardiovascular diseaseJuly 12, 2022
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
DAIC: Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the…June 21, 2023


